Patents by Inventor Kenneth W. Dobie

Kenneth W. Dobie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200115711
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 16, 2020
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Richard Lee, Kenneth W. Dobie
  • Publication number: 20200056176
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disorder, or a symptom thereof.
    Type: Application
    Filed: May 28, 2019
    Publication date: February 20, 2020
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Adam Mullick, Rosanne M. Crooke, Mark J. Graham, Kenneth W. Dobie, Thomas A. Bell, III, Richard Lee
  • Patent number: 10526604
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a nrRNA in an animal. Also provided herein are methods, compounds, and compositions for treating, ameliorating, delaying or reducing a symptom of a disease or disorder associated with a nuclear-retained RNA in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a disease or condition associated with a nuclear-retained RNA, or a symptom thereof.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: January 7, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Huynh-Hoa Bui, Kenneth W. Dobie
  • Publication number: 20180142244
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.
    Type: Application
    Filed: January 12, 2018
    Publication date: May 24, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Richard Lee, Kenneth W. Dobie
  • Patent number: 9856473
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of LMNA in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Further provided are methods of identifying cis splicing regulatory elements of a selected mRNA using the disclosed compounds.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: January 2, 2018
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie, Susan M. Freier, Stanley T. Crooke, Timothy Vickers
  • Publication number: 20170275620
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III.
    Type: Application
    Filed: March 3, 2017
    Publication date: September 28, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Kenneth W. Dobie
  • Publication number: 20170268004
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disorder, or a symptom thereof.
    Type: Application
    Filed: May 25, 2017
    Publication date: September 21, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Adam Mullick, Rosanne M. Crooke, Mark J. Graham, Kenneth W. Dobie, Thomas A. Bell, III, Richard Lee
  • Patent number: 9624496
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III. Methods of using these compounds for modulation of apolipoprotein C-III expression and for diagnosis and treatment of disease associated with expression of apolipoprotein C-III are provided.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: April 18, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Kenneth W. Dobie
  • Patent number: 9476051
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: October 25, 2016
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie, Susan M. Freier, Thomas P. Condon, Ravi Jain, Richard Alan Smith, Don W. Cleveland
  • Publication number: 20160237434
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III.
    Type: Application
    Filed: April 29, 2016
    Publication date: August 18, 2016
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Kenneth W. Dobie
  • Publication number: 20160060626
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.
    Type: Application
    Filed: August 10, 2015
    Publication date: March 3, 2016
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Richard Lee, Kenneth W. Dobie
  • Publication number: 20160060625
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disorder, or a symptom thereof.
    Type: Application
    Filed: August 7, 2015
    Publication date: March 3, 2016
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Adam Mullick, Rosanne M. Crooke, Mark J. Graham, Kenneth W. Dobie, Thomas A. Bell, III, Richard Lee
  • Patent number: 9157082
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disorder, or a symptom thereof.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: October 13, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Adam Mullick, Rosanne M. Crooke, Mark J. Graham, Kenneth W. Dobie, Richard Lee
  • Patent number: 9139831
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: September 22, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Richard Lee, Kenneth W. Dobie
  • Publication number: 20150167008
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
    Type: Application
    Filed: February 24, 2015
    Publication date: June 18, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: C. Frank Bennett, Kenneth W. Dobie
  • Patent number: 8993529
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: March 31, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie
  • Patent number: 8921331
    Abstract: Methods for slowing disease progression in an individual suffering from familial ALS are provided. Also provided are methods of increasing the survival time of an individual suffering from familial ALS. These methods employ antisense oligonucleotides targeted to SOD1, for use in inhibiting the expression of SOD1 in the central nervous system of an individual suffering from familial ALS.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: December 30, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Kenneth W. Dobie
  • Patent number: 8883997
    Abstract: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression of diacylglycerol acyltransferase 2 are provided.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: November 11, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Kenneth W. Dobie, Xing-Xian Yu, Brett P. Monia
  • Patent number: 8865884
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: October 21, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth W. Dobie, Erich Koller, Ravi Jain
  • Publication number: 20140309282
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of LMNA in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Further provided are methods of identifying cis splicing regulatory elements of a selected mRNA using the disclosed compounds.
    Type: Application
    Filed: June 25, 2014
    Publication date: October 16, 2014
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: C. Frank Bennett, Kenneth W. Dobie, Susan M. Freier, Stanley T. Crooke